JP6412248B2 - Tea fermentation - Google Patents

Tea fermentation Download PDF

Info

Publication number
JP6412248B2
JP6412248B2 JP2017505328A JP2017505328A JP6412248B2 JP 6412248 B2 JP6412248 B2 JP 6412248B2 JP 2017505328 A JP2017505328 A JP 2017505328A JP 2017505328 A JP2017505328 A JP 2017505328A JP 6412248 B2 JP6412248 B2 JP 6412248B2
Authority
JP
Japan
Prior art keywords
composition
trihydroxyphenyl
fermented
propan
catechin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2017505328A
Other languages
Japanese (ja)
Other versions
JPWO2016143745A1 (en
Inventor
栄治 福島
栄治 福島
祐子 吉本
祐子 吉本
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Suntory Holdings Ltd
Original Assignee
Suntory Holdings Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suntory Holdings Ltd filed Critical Suntory Holdings Ltd
Publication of JPWO2016143745A1 publication Critical patent/JPWO2016143745A1/en
Application granted granted Critical
Publication of JP6412248B2 publication Critical patent/JP6412248B2/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L2/00Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
    • A23L2/52Adding ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/065Diphenyl-substituted acyclic alcohols

Description

本発明は、茶発酵物に関する。更に詳しくは、茶発酵物であるカテキン代謝物を含有する各種組成物、該組成物の製造方法、該製造方法により得られた組成物を用いた飲食品の製造方法及びその飲食品に関する。   The present invention relates to a tea fermentation product. More specifically, the present invention relates to various compositions containing a catechin metabolite that is a tea fermentation product, a method for producing the composition, a method for producing a food and drink using the composition obtained by the production method, and the food and drink.

徳島県で生産される阿波番茶、高地県で生産される碁石茶など、微生物で発酵させたお茶には様々な効果効能が知られており、中には緑茶よりも高い効果を示した報告がある(非特許文献1、2)。非特許文献1では阿波番茶は緑茶よりも高いエネルギー代謝亢進作用を示すことを報告している。エネルギー代謝が亢進されると、体温が上昇し、ひいては冷え症改善、抗肥満、新陳代謝上昇など様々な健康につながることが考えられているが、微生物発酵茶におけるその効能成分についてはほとんど分かっていない。一方、非特許文献3では微生物発酵茶にはepigallocatechinが還元的に開環した1-(3’,4’,5’-trihydroxyphenyl)-3-(2’’,4’’,6’’-trihydroxyphenyl)-propan-2-olが含まれていることを報告している。これまでに1-(3’,4’,5’-trihydroxyphenyl)-3-(2’’,4’’,6’’-trihydroxyphenyl)-propan-2-olはある種の腸内細菌によって産生されることが知られているが(非特許文献4)、その生理活性についての報告はない。   Various effects are known for microorganism fermented teas, such as Awabancha produced in Tokushima Prefecture and Soseki Tea produced in Takachi Prefecture, and some reports show higher effects than green tea. (Non-Patent Documents 1 and 2) Non-Patent Document 1 reports that Awabancha has a higher energy metabolism promoting effect than green tea. When energy metabolism is promoted, it is thought that the body temperature rises and eventually leads to various health such as improvement of cold symptoms, anti-obesity, and increased metabolism, but little is known about its active ingredients in microbial fermented tea. On the other hand, in Non-Patent Document 3, 1- (3 ', 4', 5'-trihydroxyphenyl) -3- (2 '', 4 '', 6 ''-in which epigallocatechin is reductively opened in microbial fermented tea It is reported that trihydroxyphenyl) -propan-2-ol is contained. So far 1- (3 ', 4', 5'-trihydroxyphenyl) -3- (2``, 4 '', 6 ''-trihydroxyphenyl) -propan-2-ol has been produced by certain intestinal bacteria Although it is known (Non-Patent Document 4), there is no report on its physiological activity.

YAKUGAKU ZASSHI 128(7)1037-1044 (2008)YAKUGAKU ZASSHI 128 (7) 1037-1044 (2008) The Journal of Medical Investigation vol.56, p42-48 (2009)The Journal of Medical Investigation vol.56, p42-48 (2009) Jpn. J. Food Chem. Safety, Vol. 18(1) (2011)Jpn. J. Food Chem. Safety, Vol. 18 (1) (2011) J. Agric. Food Chem. 58, 1313-1321(2010)J. Agric. Food Chem. 58, 1313-1321 (2010)

本発明の課題は、1-(3’,4’,5’-trihydroxyphenyl)-3-(2’’,4’’,6’’-trihydroxyphenyl)-propan-2-olを有効成分として含有するエネルギー代謝亢進用組成物、交感神経活動亢進用組成物、脂肪燃焼促進用組成物、抗肥満用組成物、体温上昇用組成物を提供することにある。   An object of the present invention is to contain 1- (3 ′, 4 ′, 5′-trihydroxyphenyl) -3- (2``, 4 '', 6 ''-trihydroxyphenyl) -propan-2-ol as an active ingredient The object is to provide a composition for enhancing energy metabolism, a composition for enhancing sympathetic nerve activity, a composition for promoting fat burning, a composition for anti-obesity, and a composition for increasing body temperature.

また更に、本発明の課題は、前記有効成分を含有する組成物の製造方法、該製造方法により得られた組成物を用いた飲食品及びその製造方法を提供することにある。   Furthermore, the subject of this invention is providing the food-drinks using the composition obtained by this manufacturing method, the manufacturing method of the composition containing the said active ingredient, and its manufacturing method.

本発明は、下記〔1〕〜〔8〕に関する。
〔1〕 1-(3’,4’,5’-trihydroxyphenyl)-3-(2’’,4’’,6’’-trihydroxyphenyl)-propan-2-olを含有してなるエネルギー代謝亢進用組成物。
〔2〕 1-(3’,4’,5’-trihydroxyphenyl)-3-(2’’,4’’,6’’-trihydroxyphenyl)-propan-2-olを含有してなる交感神経活動亢進用組成物。
〔3〕 1-(3’,4’,5’-trihydroxyphenyl)-3-(2’’,4’’,6’’-trihydroxyphenyl)-propan-2-olを含有してなる脂肪燃焼促進用組成物。
〔4〕 1-(3’,4’,5’-trihydroxyphenyl)-3-(2’’,4’’,6’’-trihydroxyphenyl)-propan-2-olを含有してなる抗肥満用組成物。
〔5〕 1-(3’,4’,5’-trihydroxyphenyl)-3-(2’’,4’’,6’’-trihydroxyphenyl)-propan-2-olを含有してなる体温上昇用組成物。
〔6〕 茶抽出液をラクトバチルス・ペントーサスに属する菌で発酵する工程を含むことを特徴とする、1-(3’,4’,5’-trihydroxyphenyl)-3-(2’’,4’’,6’’-trihydroxyphenyl)-propan-2-ol含有組成物の製造方法。
〔7〕 前記〔6〕記載の製造方法により得られた組成物を、飲食品の原料として使用することを特徴とする、飲食品の製造方法。
〔8〕 前記〔6〕記載の製造方法により得られた組成物を含有してなる、飲食品。
The present invention relates to the following [1] to [8].
[1] 1- (3 ', 4', 5'-trihydroxyphenyl) -3- (2 '', 4 '', 6 ''-trihydroxyphenyl) -propan-2-ol for enhancing energy metabolism Composition.
[2] Increased sympathetic nerve activity containing 1- (3 ', 4', 5'-trihydroxyphenyl) -3- (2 '', 4 '', 6 ''-trihydroxyphenyl) -propan-2-ol Composition.
[3] Promotion of fat burning comprising 1- (3 ', 4', 5'-trihydroxyphenyl) -3- (2 '', 4 '', 6 ''-trihydroxyphenyl) -propan-2-ol Composition.
[4] Anti-obesity composition comprising 1- (3 ', 4', 5'-trihydroxyphenyl) -3- (2 '', 4 '', 6 ''-trihydroxyphenyl) -propan-2-ol object.
[5] Composition for raising body temperature comprising 1- (3 ', 4', 5'-trihydroxyphenyl) -3- (2 '', 4 '', 6 ''-trihydroxyphenyl) -propan-2-ol object.
[6] 1- (3 ', 4', 5'-trihydroxyphenyl) -3- (2 '', 4 ', characterized by comprising a step of fermenting tea extract with bacteria belonging to Lactobacillus pentosus A method for producing a composition containing ', 6''-trihydroxyphenyl) -propan-2-ol.
[7] A method for producing a food or drink, wherein the composition obtained by the production method according to [6] is used as a raw material for the food or drink.
[8] A food / beverage product comprising the composition obtained by the production method according to [6].

本発明のエネルギー代謝亢進用組成物は、エネルギー代謝の亢進作用に優れるという優れた効果を奏する。本発明の交感神経活動亢進用組成物は、交感神経活動の亢進作用に優れるという優れた効果を奏する。本発明の脂肪燃焼促進用組成物は、脂肪燃焼の促進作用に優れるという優れた効果を奏する。本発明の抗肥満用組成物は、抗肥満作用に優れるという優れた効果を奏する。本発明の体温上昇用組成物は、体温の上昇作用に優れるという優れた効果を奏する。   The composition for enhancing energy metabolism of the present invention has an excellent effect of being excellent in enhancing energy metabolism. The composition for enhancing sympathetic nerve activity of the present invention has an excellent effect of being excellent in enhancing the sympathetic nerve activity. The composition for promoting fat burning according to the present invention has an excellent effect of being excellent in promoting fat burning. The anti-obesity composition of the present invention has an excellent effect of being excellent in anti-obesity action. The composition for increasing body temperature of the present invention has an excellent effect of being excellent in increasing body temperature.

また、本発明の製造方法により得られる組成物は、1-(3’,4’,5’-trihydroxyphenyl)-3-(2’’,4’’,6’’-trihydroxyphenyl)-propan-2-olを高濃度で含有することから、エネルギー代謝の亢進作用に優れる、交感神経活動の亢進作用に優れる、脂肪燃焼の促進作用に優れる、抗肥満作用に優れる、体温の上昇作用に優れるといった優れた効果を奏する。   The composition obtained by the production method of the present invention is 1- (3 ′, 4 ′, 5′-trihydroxyphenyl) -3- (2 '', 4 '', 6 ''-trihydroxyphenyl) -propan-2 -ol is contained in a high concentration, so it excels in energy metabolism enhancement, sympathetic nerve activity enhancement, fat burning promotion, anti-obesity, excellent body temperature elevation Has an effect.

図1は、茶エキスの発酵液における1-(3’,4’,5’-trihydroxyphenyl)-3-(2’’,4’’,6’’-trihydroxyphenyl)-propan-2-olの生成を示す代表的なHPLCチャートの結果を示す図である(A:発酵カテキン精製品、B:発酵前の茶エキス、C:発酵後の茶エキス(TUA4337Lを用いて72時間培養後))。Figure 1 shows the formation of 1- (3 ', 4', 5'-trihydroxyphenyl) -3- (2 '', 4 '', 6 ''-trihydroxyphenyl) -propan-2-ol in the fermentation broth of tea extract (A: Fermented catechin purified product, B: Tea extract before fermentation, C: Tea extract after fermentation (after culturing for 72 hours using TUA4337L)). 図2は、茶エキスの発酵液における1-(3’,4’,5’-trihydroxyphenyl)-3-(2’’,4’’,6’’-trihydroxyphenyl)-propan-2-olの経時的な生成量を示す図である。Figure 2 shows the time course of 1- (3 ', 4', 5'-trihydroxyphenyl) -3- (2 '', 4 '', 6 ''-trihydroxyphenyl) -propan-2-ol in the tea extract fermentation broth It is a figure which shows a typical production amount. 図3は、種々の乳酸菌による1-(3’,4’,5’-trihydroxyphenyl)-3-(2’’,4’’,6’’-trihydroxyphenyl)-propan-2-olの生成結果を示す図である。Fig. 3 shows the production results of 1- (3 ', 4', 5'-trihydroxyphenyl) -3- (2 '', 4 '', 6 ''-trihydroxyphenyl) -propan-2-ol by various lactic acid bacteria. FIG. 図4は、1-(3’,4’,5’-trihydroxyphenyl)-3-(2’’,4’’,6’’-trihydroxyphenyl)-propan-2-olによる交感神経活動の亢進結果を示す図である。Figure 4 shows the results of enhancement of sympathetic nerve activity by 1- (3 ', 4', 5'-trihydroxyphenyl) -3- (2 '', 4 '', 6 ''-trihydroxyphenyl) -propan-2-ol FIG. 図5は、1-(3’,4’,5’-trihydroxyphenyl)-3-(2’’,4’’,6’’-trihydroxyphenyl)-propan-2-olの連続投与における投与4日目の消費カロリーを示す図である(*:p<0.05 t-test)。FIG. 5 shows the fourth day after administration of 1- (3 ′, 4 ′, 5′-trihydroxyphenyl) -3- (2 ″, 4 ″, 6 ″ -trihydroxyphenyl) -propan-2-ol. It is a figure which shows the calorie consumption of (*: p <0.05 t-test). 図6は、1-(3’,4’,5’-trihydroxyphenyl)-3-(2’’,4’’,6’’-trihydroxyphenyl)-propan-2-olによる呼吸商の変化を示す図である(*:p<0.05 t-test)。Fig. 6 shows changes in respiratory quotient by 1- (3 ', 4', 5'-trihydroxyphenyl) -3- (2 '', 4 '', 6 ''-trihydroxyphenyl) -propan-2-ol (*: P <0.05 t-test). 図7は、1-(3’,4’,5’-trihydroxyphenyl)-3-(2’’,4’’,6’’-trihydroxyphenyl)-propan-2-olによる体温上昇の結果を示す図である(*:p<0.05 t-test)。FIG. 7 is a graph showing the results of body temperature increase by 1- (3 ′, 4 ′, 5′-trihydroxyphenyl) -3- (2 ″, 4 ″, 6 ″ -trihydroxyphenyl) -propan-2-ol (*: P <0.05 t-test). 図8は、1-(3’,4’,5’-trihydroxyphenyl)-3-(2’’,4’’,6’’-trihydroxyphenyl)-propan-2-olによる体重増加の抑制結果を示す図である(†:p<0.1 t-test)。FIG. 8 shows the results of suppression of weight gain by 1- (3 ′, 4 ′, 5′-trihydroxyphenyl) -3- (2 ″, 4 ″, 6 ″ -trihydroxyphenyl) -propan-2-ol It is a figure (†: p <0.1 t-test).

本発明のエネルギー代謝亢進用組成物、交感神経活動亢進用組成物、脂肪燃焼促進用組成物、抗肥満用組成物、又は体温上昇用組成物は、1-(3’,4’,5’-trihydroxyphenyl)-3-(2’’,4’’,6’’-trihydroxyphenyl)-propan-2-olを有効成分として含有することを特徴とする。即ち、本発明の組成物は、それぞれ、1-(3’,4’,5’-trihydroxyphenyl)-3-(2’’,4’’,6’’-trihydroxyphenyl)-propan-2-olを有効成分とする、エネルギー代謝亢進剤、交感神経活動亢進剤、脂肪燃焼促進剤、抗肥満剤、又は体温上昇剤でもある。本明細書において、「エネルギー代謝」とはATPがADPに変換されるときに遊離するエネルギーを筋収縮、神経伝達、物質構成、体温調節などに変換する過程のことを意味し、酸素消費量および二酸化炭素排出量からエネルギー消費量として算出される。「交感神経」とは熱産生組織である褐色脂肪組織における交感神経を意味し、交感神経活動が亢進されるとエネルギー代謝が亢進し、体温上昇、脂肪燃焼、ひいては抗肥満などにつながる。「脂肪燃焼」とは酸素消費量に対する二酸化炭素排出量の体積比である呼吸商を指標にしており、呼吸商が低下するほど脂肪を燃焼していることを意味する。「抗肥満」とは体重の増加が抑制されること又は体重が減少することを意味する。   The composition for enhancing energy metabolism, the composition for enhancing sympathetic nerve activity, the composition for promoting fat burning, the composition for anti-obesity, or the composition for increasing body temperature of the present invention is 1- (3 ′, 4 ′, 5 ′ -trihydroxyphenyl) -3- (2 '', 4 '', 6 ''-trihydroxyphenyl) -propan-2-ol as an active ingredient. That is, the composition of the present invention contains 1- (3 ′, 4 ′, 5′-trihydroxyphenyl) -3- (2``, 4 '', 6 ''-trihydroxyphenyl) -propan-2-ol, respectively. It is also an energy metabolism enhancer, a sympathetic nerve activity enhancer, a fat burning accelerator, an anti-obesity agent, or a body temperature increasing agent as an active ingredient. As used herein, “energy metabolism” means the process of converting energy released when ATP is converted to ADP into muscle contraction, neurotransmission, substance composition, thermoregulation, etc., and oxygen consumption and Calculated as energy consumption from carbon dioxide emissions. “Sympathetic nerve” means a sympathetic nerve in brown adipose tissue, which is a heat-producing tissue. When sympathetic nerve activity is increased, energy metabolism is increased, leading to increased body temperature, fat burning, and anti-obesity. “Fat burning” is based on the respiratory quotient, which is the volume ratio of the carbon dioxide emission to the oxygen consumption, and means that fat is burned as the respiratory quotient decreases. “Anti-obesity” means that weight gain is suppressed or weight is decreased.

1-(3’,4’,5’-trihydroxyphenyl)-3-(2’’,4’’,6’’-trihydroxyphenyl)-propan-2-olは、以下の式(I):   1- (3 ′, 4 ′, 5′-trihydroxyphenyl) -3- (2 ″, 4 ″, 6 ″ -trihydroxyphenyl) -propan-2-ol is represented by the following formula (I):

Figure 0006412248
Figure 0006412248

で表される構造を有するものであり、カテキンの一種であるepigallocatechinの代謝産物として知られている。 It is known as a metabolite of epigallocatechin, which is a kind of catechin.

1-(3’,4’,5’-trihydroxyphenyl)-3-(2’’,4’’,6’’-trihydroxyphenyl)-propan-2-olは、公知の有機化学合成方法に従って調製することができ、例えば、epigallocatechinを材料として白金族触媒を利用した水素化によって調製することができる。また1-(3’,4’,5’-trihydroxyphenyl)-3-(2’’,4’’,6’’-trihydroxyphenyl)-propan-2-olは生物学的な変換によってepigallocatechinから生成することが知られている(非特許文献4)。本発明では、例えば、お茶エキスを用いてラクトバチルス・ペントーサスに属する菌を培養することにより得ることができる。   1- (3 ', 4', 5'-trihydroxyphenyl) -3- (2``, 4 '', 6 ''-trihydroxyphenyl) -propan-2-ol should be prepared according to known organic chemical synthesis methods For example, it can be prepared by hydrogenation using a platinum group catalyst using epigallocatechin as a material. 1- (3 ', 4', 5'-trihydroxyphenyl) -3- (2``, 4 '', 6 ''-trihydroxyphenyl) -propan-2-ol is also produced from epigallocatechin by biological transformation It is known (Non-Patent Document 4). In the present invention, for example, it can be obtained by culturing bacteria belonging to Lactobacillus pentosas using a tea extract.

ラクトバチルス・ペントーサスに属する菌としては、公知のものであれば特に限定はなく、例えば、識別の表示NRIC 0883、受託番号NITE BP−1479として、国際受託日2012年12月10日付で、独立行政法人 製品評価技術基盤機構 特許微生物寄託センター(日本国千葉県木更津市かずさ鎌足2−5−8)に寄託されているラクトバチルス・ペントーサス TUA4337L株を好適に用いることができる。以下、ラクトバチルス・ペントーサス TUA4337L株のことを、TUA4337L株と略記する。   The microorganism belonging to Lactobacillus pentosas is not particularly limited as long as it is a known one. For example, as an indication of identification NRIC 0883 and accession number NITE BP-1479, the international administration date is December 10, 2012, The Lactobacillus pentosaus TUA4337L strain deposited at the Japan Institute for Product Evaluation Technology Patent Microorganism Deposit Center (Kazusa Kamafoot 2-5-8, Kisarazu City, Chiba Prefecture, Japan) can be suitably used. Hereinafter, the Lactobacillus pentosus TUA4337L strain is abbreviated as TUA4337L strain.

なお、得られた処理物に対しては、所望により、ろ過、遠心分離、濃縮、限外ろ過、凍結乾燥、粉末化、分画等の処理を公知の方法に従って行ってもよい。よって、例えば、1-(3’,4’,5’-trihydroxyphenyl)-3-(2’’,4’’,6’’-trihydroxyphenyl)-propan-2-olを含有する組成物をそれぞれ、本発明のエネルギー代謝亢進用組成物、交感神経活動亢進用組成物、脂肪燃焼促進用組成物、抗肥満用組成物、又は体温上昇用組成物の有効成分として提供することができる。   In addition, with respect to the obtained processed material, you may perform processes, such as filtration, centrifugation, concentration, ultrafiltration, lyophilization | freeze-drying, pulverization, and fractionation, if desired. Thus, for example, each of the compositions containing 1- (3 ', 4', 5'-trihydroxyphenyl) -3- (2 '', 4 '', 6 ''-trihydroxyphenyl) -propan-2-ol, It can be provided as an active ingredient of the composition for enhancing energy metabolism, the composition for enhancing sympathetic activity, the composition for promoting fat burning, the composition for anti-obesity, or the composition for raising body temperature of the present invention.

以上のようにして得られた1-(3’,4’,5’-trihydroxyphenyl)-3-(2’’,4’’,6’’-trihydroxyphenyl)-propan-2-olは、褐色脂肪組織の交感神経活動を刺激して、褐色脂肪組織の活性化、例えば、エネルギー代謝の亢進作用、体温の上昇作用、脂肪の燃焼作用、ひいては抗肥満作用を発揮するために使用することができる。   1- (3 ', 4', 5'-trihydroxyphenyl) -3- (2``, 4 '', 6 ''-trihydroxyphenyl) -propan-2-ol obtained as described above is a brown fat It can be used to stimulate the sympathetic nerve activity of the tissue and to activate brown adipose tissue, for example, to exert an energy metabolism enhancing effect, a body temperature increasing effect, a fat burning effect, and thus an anti-obesity effect.

本発明のエネルギー代謝亢進用組成物、交感神経活動亢進用組成物、脂肪燃焼促進用組成物、抗肥満用組成物、又は体温上昇用組成物は、それらの投与形態は限定されない。なお、本明細書において、投与とは、投与、摂取、服用、飲用の全態様を含むものとして用いられる。   The administration form of the composition for enhancing energy metabolism, the composition for enhancing sympathetic activity, the composition for promoting fat burning, the composition for anti-obesity, or the composition for raising body temperature of the present invention is not limited. In the present specification, the term “administration” is used to include all modes of administration, ingestion, taking, and drinking.

本発明のエネルギー代謝亢進用組成物、交感神経活動亢進用組成物、脂肪燃焼促進用組成物、抗肥満用組成物、又は体温上昇用組成物の投与による効能としては、それらの投与によって発現する効能であれば特に限定はない。例えば、体温上昇、冷え性改善、抗肥満、内臓脂肪低減、美容、新陳代謝促進、免疫賦活、抗疲労、抗鬱等が例示される。   The effects of administration of the composition for enhancing energy metabolism, the composition for enhancing sympathetic nerve activity, the composition for promoting fat burning, the composition for anti-obesity, or the composition for increasing body temperature of the present invention are manifested by their administration. There is no particular limitation as long as it is effective. For example, body temperature rise, cooling improvement, anti-obesity, visceral fat reduction, beauty, promotion of metabolism, immune activation, anti-fatigue, antidepressant and the like are exemplified.

本発明のエネルギー代謝亢進用組成物、交感神経活動亢進用組成物、脂肪燃焼促進用組成物、抗肥満用組成物、又は体温上昇用組成物は、例えば、1-(3’,4’,5’-trihydroxyphenyl)-3-(2’’,4’’,6’’-trihydroxyphenyl)-propan-2-olに、所望により溶剤、分散剤、乳化剤、緩衝剤、安定剤、賦形剤、結合剤、崩壊剤、滑沢剤等を加えて、公知の方法に従って、錠剤、顆粒剤、散剤、粉末剤、カプセル剤等の固形剤や、通常液剤、懸濁剤、乳剤等の液剤等に製剤化することもできる。   The composition for enhancing energy metabolism, the composition for enhancing sympathetic activity, the composition for promoting fat burning, the composition for anti-obesity, or the composition for increasing body temperature of the present invention is, for example, 1- (3 ′, 4 ′, 5'-trihydroxyphenyl) -3- (2``, 4 '', 6 ''-trihydroxyphenyl) -propan-2-ol, if desired, solvent, dispersant, emulsifier, buffer, stabilizer, excipient, Add binders, disintegrants, lubricants, etc., and in accordance with known methods, into solids such as tablets, granules, powders, powders, capsules, etc., or liquids such as normal solutions, suspensions, emulsions, etc. It can also be formulated.

また、前記形態における1-(3’,4’,5’-trihydroxyphenyl)-3-(2’’,4’’,6’’-trihydroxyphenyl)-propan-2-olの含有量は、それらの投与形態、投与方法などを考慮し、本発明の所望の効果の発現が得られ得るような量であればよく、特に限定されるものではない。1-(3’,4’,5’-trihydroxyphenyl)-3-(2’’,4’’,6’’-trihydroxyphenyl)-propan-2-olの含有比率(含有量)としては通常0.0001〜100重量%、好ましくは0.001〜30重量%、より好ましくは0.01〜5重量%程度である。なお、1-(3’,4’,5’-trihydroxyphenyl)-3-(2’’,4’’,6’’-trihydroxyphenyl)-propan-2-olの含有量は、公知の方法に従って測定することができ、例えば、HPLCに供することで測定することができる。   The content of 1- (3 ′, 4 ′, 5′-trihydroxyphenyl) -3- (2``, 4 '', 6 ''-trihydroxyphenyl) -propan-2-ol in the above form is Considering the administration form, administration method, etc., the amount is not particularly limited as long as the desired effect of the present invention can be obtained. The content ratio (content) of 1- (3 ', 4', 5'-trihydroxyphenyl) -3- (2``, 4 '', 6 ''-trihydroxyphenyl) -propan-2-ol is usually 0.0001 ~ It is about 100% by weight, preferably 0.001 to 30% by weight, more preferably about 0.01 to 5% by weight. The content of 1- (3 ', 4', 5'-trihydroxyphenyl) -3- (2``, 4 '', 6 ''-trihydroxyphenyl) -propan-2-ol was measured according to a known method For example, it can be measured by subjecting it to HPLC.

本発明のエネルギー代謝亢進用組成物、交感神経活動亢進用組成物、脂肪燃焼促進用組成物、抗肥満用組成物、又は体温上昇用組成物は、それらの形態に応じた適当な投与方法で投与される。例えば内用、外用及び注射により投与することができる。内用の場合は、例えば、経口により摂取し得、注射の場合は、例えば、静脈内、筋肉内、皮下、皮内などに投与し得、外用の場合は、例えば、座剤等の外用剤として、その適する投与方法により投与すればよい。   The composition for enhancing energy metabolism, the composition for enhancing sympathetic nerve activity, the composition for promoting fat burning, the composition for anti-obesity, or the composition for raising body temperature of the present invention can be administered by an appropriate administration method depending on the form. Be administered. For example, it can be administered by internal use, external use or injection. For internal use, for example, it can be taken orally, for injection it can be administered, for example, intravenously, intramuscularly, subcutaneously, intradermally, for external use, for example, external preparations such as suppositories As such, it may be administered by its suitable administration method.

本発明のエネルギー代謝亢進用組成物、交感神経活動亢進用組成物、脂肪燃焼促進用組成物、抗肥満用組成物、又は体温上昇用組成物の投与量は、それらの形態、投与方法、使用目的及び当該組成物の投与対象であるヒト又は患獣の年齢、体重、症状によって適宜設定され一定ではない。例えば、本発明における1-(3’,4’,5’-trihydroxyphenyl)-3-(2’’,4’’,6’’-trihydroxyphenyl)-propan-2-olの有効ヒト摂取量としては、体重50kgのヒトで1日当たり、好ましくは1mg〜10g、より好ましくは10mg〜3g、さらに好ましくは100mg〜1g程度である。また、投与は、所望の投与量範囲内において、1日内において単回で、又は数回に分けて行ってもよい。投与期間も任意である。   The dosage of the composition for enhancing energy metabolism, the composition for enhancing sympathetic nerve activity, the composition for promoting fat burning, the composition for anti-obesity, or the composition for increasing body temperature of the present invention is their form, administration method, use It is appropriately set according to the purpose and the age, weight, and symptoms of a human or animal subject to whom the composition is administered, and is not constant. For example, as the effective human intake of 1- (3 ′, 4 ′, 5′-trihydroxyphenyl) -3- (2``, 4 '', 6 ''-trihydroxyphenyl) -propan-2-ol in the present invention, It is preferably about 1 mg to 10 g, more preferably about 10 mg to 3 g, and still more preferably about 100 mg to 1 g per day for a human weighing 50 kg. Further, the administration may be performed once or divided into several times within one day within a desired dose range. The administration period is also arbitrary.

本明細書中において本発明のエネルギー代謝亢進用組成物、交感神経活動亢進用組成物、脂肪燃焼促進用組成物、抗肥満用組成物、又は体温上昇用組成物の投与対象とは、好ましくはエネルギー代謝の亢進、交感神経活動の亢進、脂肪の燃焼、体重増加の抑制又は体重減少、あるいは体温の上昇の作用発現を治療又は予防に必要とするヒトであるが、ウシ、ウマ、ヤギ等の家畜動物、イヌ、ネコ、ウサギ等のペット動物、又は、マウス、ラット、モルモット、サル等の実験動物であってもよい。また、投与対象として、エネルギー代謝の亢進を必要とする個体だけでなく、エネルギー代謝は低くはないが、体重の上昇を抑制する必要のある個体、冷えを抑制する必要のある個体、内臓脂肪の増加を抑制する必要のある個体、新陳代謝の低下を抑制する必要のある個体、風邪を治療又は予防したい個体、美容の維持を必要とする個体、疲れを抑制する必要のある個体も含まれる。   In the present specification, the subject of administration of the composition for enhancing energy metabolism, the composition for enhancing sympathetic nerve activity, the composition for promoting fat burning, the composition for anti-obesity, or the composition for increasing body temperature of the present invention is preferably It is a human who requires treatment or prevention of increased energy metabolism, increased sympathetic nerve activity, fat burning, weight gain suppression or weight loss, or increased body temperature, such as cows, horses, goats, etc. It may be a domestic animal, a pet animal such as a dog, a cat or a rabbit, or a laboratory animal such as a mouse, rat, guinea pig or monkey. In addition, not only individuals who need increased energy metabolism but also energy metabolism is not low, but individuals who need to suppress weight gain, individuals who need to suppress chilling, visceral fat An individual who needs to suppress the increase, an individual who needs to suppress a decrease in metabolism, an individual who wants to treat or prevent a cold, an individual who needs to maintain beauty, and an individual who needs to suppress fatigue are included.

本発明はまた、エネルギー代謝の亢進、交感神経活動の亢進、脂肪燃焼の促進、体重増加の抑制又は体重減少、あるいは体温の上昇を必要とする個体に、1-(3’,4’,5’-trihydroxyphenyl)-3-(2’’,4’’,6’’-trihydroxyphenyl)-propan-2-olを、あるいは1-(3’,4’,5’-trihydroxyphenyl)-3-(2’’,4’’,6’’-trihydroxyphenyl)-propan-2-olを含有する組成物をその治療有効量を投与することを含む、エネルギー代謝の亢進方法、交感神経活動の亢進方法、脂肪燃焼の促進方法、体重増加の抑制又は体重減少方法、あるいは体温の上昇方法を提供する。なお、エネルギー代謝の亢進、交感神経活動の亢進、脂肪燃焼の促進、体重増加の抑制又は体重減少、あるいは体温上昇を必要とする個体とは、前記した本発明のエネルギー代謝亢進用組成物、交感神経活動亢進用組成物、脂肪燃焼促進用組成物、抗肥満用組成物、体温上昇用組成物の投与対象と同様である。   The present invention also provides 1- (3 ′, 4 ′, 5) to individuals who need increased energy metabolism, increased sympathetic activity, promoted fat burning, reduced weight gain or reduced body weight, or increased body temperature. '-trihydroxyphenyl) -3- (2``, 4' ', 6' '-trihydroxyphenyl) -propan-2-ol or 1- (3', 4 ', 5'-trihydroxyphenyl) -3- (2 Administration of a therapeutically effective amount of a composition containing '', 4 '', 6 ''-trihydroxyphenyl) -propan-2-ol, a method for enhancing energy metabolism, a method for enhancing sympathetic nerve activity, a fat Provided are a method for promoting combustion, a method for suppressing weight gain or a method for reducing weight, or a method for increasing body temperature. In addition, an individual who needs an increase in energy metabolism, an increase in sympathetic nerve activity, an acceleration of fat burning, a suppression of weight gain or a decrease in body weight, or an increase in body temperature refers to the composition for enhancing energy metabolism of the present invention described above, sympathy This is the same as the administration subject of the composition for enhancing nerve activity, the composition for promoting fat burning, the composition for anti-obesity, and the composition for raising body temperature.

また、本明細書中において治療有効量とは、1-(3’,4’,5’-trihydroxyphenyl)-3-(2’’,4’’,6’’-trihydroxyphenyl)-propan-2-olを上記個体に投与した場合に、投与していない個体と比較して、エネルギー代謝が亢進する量、交感神経活動が亢進する量、脂肪燃焼が促進する量、体重増加を抑制又は体重減少する量、あるいは体温が上昇する量のことである。具体的な有効量としては、投与形態、投与方法、使用目的及び個体の年齢、体重、症状等によって適宜設定され一定ではない。   In the present specification, the therapeutically effective amount is 1- (3 ′, 4 ′, 5′-trihydroxyphenyl) -3- (2``, 4 '', 6 ''-trihydroxyphenyl) -propan-2- When ol is administered to the above individuals, the amount of increased energy metabolism, the amount of enhanced sympathetic nerve activity, the amount of promoting fat burning, the suppression of weight gain or the reduction of body weight compared to individuals not administered The amount, or the amount by which body temperature rises. The specific effective amount is appropriately set according to the administration form, administration method, purpose of use, individual age, weight, symptoms, etc., and is not constant.

本発明の治療方法においては、前記治療有効量となるよう、1-(3’,4’,5’-trihydroxyphenyl)-3-(2’’,4’’,6’’-trihydroxyphenyl)-propan-2-olをそのまま、また、1-(3’,4’,5’-trihydroxyphenyl)-3-(2’’,4’’,6’’-trihydroxyphenyl)-propan-2-olを含有する組成物を投与することができる。また、投与方法にも限定はなく、例えば、経口投与により投与することができる。   In the treatment method of the present invention, 1- (3 ′, 4 ′, 5′-trihydroxyphenyl) -3- (2 ″, 4 ″, 6 ″ -trihydroxyphenyl) -propan is used so that the therapeutically effective amount is obtained. -2-ol as it is, and also contains 1- (3 ', 4', 5'-trihydroxyphenyl) -3- (2 '', 4 '', 6 ''-trihydroxyphenyl) -propan-2-ol The composition can be administered. Moreover, there is no limitation also in the administration method, For example, it can administer by oral administration.

本発明の治療方法によれば、副作用を生じることなく、エネルギー代謝を亢進、交感神経活動を亢進、脂肪燃焼を促進、抗肥満(体重増加を抑制又は体重を減少させる)、あるいは体温を上昇することが可能となる。   According to the treatment method of the present invention, without causing side effects, energy metabolism is enhanced, sympathetic nerve activity is enhanced, fat burning is promoted, anti-obesity (suppresses weight gain or decreases body weight), or increases body temperature. It becomes possible.

また、本発明の組成物としては、例えば、茶抽出液をラクトバチルス・ペントーサスに属する菌で発酵する工程を含むことを特徴とする製造方法により得られる組成物が好適例として挙げられる。なお、前記製造方法のことを本発明の製造方法と記載することもある。   Moreover, as a composition of this invention, the composition obtained by the manufacturing method characterized by including the process of fermenting a tea extract with the microbe which belongs to a Lactobacillus pentosus, for example is mentioned as a suitable example. In addition, the said manufacturing method may be described as the manufacturing method of this invention.

茶葉には種々のカテキン類が含まれ、阿波番茶や碁石茶などの発酵樽で自然発酵させたいわゆる微生物発酵茶葉(後発酵茶葉)には前記式(I)で表される化合物も含まれていることが知られている。しかしながら、前記式(I)で表される化合物を産生する微生物種は知られておらず、特定の微生物種を用いて発酵させるのではなく、前述の後発酵茶葉のように自然発酵によって非効率的に前記式(I)で表される化合物が他の化合物と共に生成されている。また後発酵茶葉は原料を固体の状態のまま発酵させて(固体発酵)、最終的に発酵させた固体(茶葉)が製品になることから、飲用時にはエキスを別途抽出する必要があり、その際に前記式(I)で表される化合物が上手く抽出されなかったり、分解されてしまったりする可能性もある。本発明者らは、意外にも、茶葉からの抽出液にラクトバチルス・ペントーサスに属する菌を接触させることで、前記式(I)で表される化合物が高含有で含まれる組成物が得られ、該組成物がエネルギー代謝亢進作用を有することを初めて見出した。即ち、本発明の一態様としては、茶抽出液をラクトバチルス・ペントーサスに属する菌で発酵することで、epigallocatechinから、1-(3’,4’,5’-trihydroxyphenyl)-3-(2’’,4’’,6’’-trihydroxyphenyl)-propan-2-olへの代謝が促進されることを、本発明者らが見出したことに基づくものである。茶葉からの抽出液を発酵させることから、飲用時に別途エキスを抽出する後発酵茶葉とは異なり、発酵液をそのまま使用でき、1-(3’,4’,5’-trihydroxyphenyl)-3-(2’’,4’’,6’’-trihydroxyphenyl)-propan-2-olを容易に摂取することができる。以降、茶抽出液を用いて得られる1-(3’,4’,5’-trihydroxyphenyl)-3-(2’’,4’’,6’’-trihydroxyphenyl)-propan-2-olのことを、本発明の発酵カテキンと記載し、また、茶抽出液を用いて得られる1-(3’,4’,5’-trihydroxyphenyl)-3-(2’’,4’’,6’’-trihydroxyphenyl)-propan-2-ol含有組成物のことを本発明の発酵カテキン含有組成物と記載することもある。   The tea leaves contain various catechins, and so-called microbial fermented tea leaves (post-fermented tea leaves) naturally fermented in fermentation barrels such as Awaban tea and Soseki tea also contain compounds represented by the above formula (I). It is known that However, the microbial species that produce the compound represented by the formula (I) is not known and is not fermented using a specific microbial species. In particular, the compound represented by the formula (I) is produced together with other compounds. In addition, post-fermented tea leaves are fermented with the raw materials in a solid state (solid fermentation), and finally fermented solids (tea leaves) become products, so it is necessary to extract the extract separately when drinking, Further, the compound represented by the formula (I) may not be extracted well or may be decomposed. The present inventors have surprisingly obtained a composition containing a high content of the compound represented by the formula (I) by bringing a fungus belonging to Lactobacillus pentosas into contact with an extract from tea leaves. For the first time, it has been found that the composition has an action of enhancing energy metabolism. That is, as one aspect of the present invention, 1- (3 ′, 4 ′, 5′-trihydroxyphenyl) -3- (2 ′) is obtained from epigallocatechin by fermenting the tea extract with a bacterium belonging to Lactobacillus pentosas. This is based on what the present inventors have found that metabolism to ', 4' ', 6' '-trihydroxyphenyl) -propan-2-ol is promoted. Unlike fermented tea leaves, which extract the extract from tea leaves and extract the extract separately at the time of drinking, the fermented liquid can be used as is, and 1- (3 ', 4', 5'-trihydroxyphenyl) -3- ( 2 '', 4 '', 6 ''-trihydroxyphenyl) -propan-2-ol can be easily ingested. Hereinafter, 1- (3 ', 4', 5'-trihydroxyphenyl) -3- (2 '', 4 '', 6 ''-trihydroxyphenyl) -propan-2-ol obtained using tea extract 1- (3 ′, 4 ′, 5′-trihydroxyphenyl) -3- (2``, 4 '', 6 '' obtained using the tea extract -trihydroxyphenyl) -propan-2-ol-containing composition may be described as the fermented catechin-containing composition of the present invention.

本発明で用いられる茶抽出液としては、例えば、茶葉を公知の溶媒で抽出することにより得られたものを使用することができる。また、本発明においては、本発明の発酵カテキンをより多く産生させる観点から、本発明の発酵カテキンの前駆体であるepigallocatechinを多く含有する抽出液を用いてもよい。   As the tea extract used in the present invention, for example, one obtained by extracting tea leaves with a known solvent can be used. Moreover, in this invention, you may use the extract containing many epigallocatechin which is the precursor of the fermentation catechin of this invention from a viewpoint of producing more fermented catechin of this invention.

本明細書における「茶葉」とは、緑茶、紅茶、ウーロン茶などの茶葉が挙げられる。茶葉の種類としては、ツバキ科の植物、例えばカメリア属の茶(Camellia sinensis)の葉が挙げられる。本発明においては、茶葉そのものであっても、粉砕品であってもよい。   As used herein, “tea leaves” include tea leaves such as green tea, black tea, and oolong tea. Examples of the types of tea leaves include Camellia plant, for example, Camellia sinensis leaves. In the present invention, the tea leaf itself or a pulverized product may be used.

溶媒としては、例えば、水、エチルアルコール、イソプロパノール等の親水性有機溶剤の何れかまたはこれらを適宜組み合わせたものが挙げられる。   Examples of the solvent include any one of hydrophilic organic solvents such as water, ethyl alcohol, and isopropanol, or a combination of these appropriately.

抽出条件は、用いる装置や使用量に応じて一概に設定されるものではないが、例えば、抽出温度は30〜100℃、好ましくは40〜80℃である。なお、本発明においては、茶抽出液として市販品を用いてもよい。   The extraction conditions are not generally set according to the apparatus used and the amount used, but for example, the extraction temperature is 30 to 100 ° C, preferably 40 to 80 ° C. In the present invention, a commercial product may be used as the tea extract.

ここで用いられるラクトバチルス・ペントーサスに属する菌としては、前記したものを同様に用いることができる。   As the bacteria belonging to Lactobacillus pentosas used here, those described above can be similarly used.

なお、本発明における菌株としては、ラクトバチルス・ペントーサスに属する菌(生菌及び死菌)そのもの、当該乳酸菌含有物、乳酸菌処理物等の各種形態を挙げることができる。生菌は当該乳酸菌培養液等の乳酸菌含有物から得ることができる。死菌は、例えば、生菌に対して加熱、紫外線照射、ホルマリン処理、酸処理などを行うことにより得ることができる。得られた生菌、死菌は、さらに磨砕や破砕等により、処理物とすることができる。なお、前記各形態における乳酸菌は、epigallocatechinに作用して本発明の発酵カテキンを産生するのであれば、生菌であることが好ましいが、死菌が混在していてもよい。   In addition, as strains in the present invention, various forms such as bacteria belonging to Lactobacillus pentosasus (live bacteria and dead bacteria) themselves, lactic acid bacteria-containing substances, and processed lactic acid bacteria can be exemplified. Viable bacteria can be obtained from lactic acid bacteria-containing materials such as the lactic acid bacteria culture solution. Dead bacteria can be obtained, for example, by subjecting live bacteria to heating, ultraviolet irradiation, formalin treatment, acid treatment, and the like. The obtained live bacteria and dead bacteria can be further processed by grinding or crushing. In addition, as long as the lactic acid bacteria in each said form act on epigallocatechin and produce the fermentation catechin of this invention, although it is preferable that it is a living microbe, a dead microbe may be mixed.

前記菌による発酵条件としては、茶抽出液中での発酵であれば他の条件は特に制限されず、例えば、炭素源、窒素源、無機塩類、有機栄養素などを含む添加物を添加して発酵させてもよい。具体的には、例えば、酵母における成分を酵素や熱水などの処理により抽出されたエキスである酵母エキスを窒素源として茶抽出液に添加することが出来る。発酵温度は、好ましくは10℃以上、より好ましくは15℃以上、更に好ましくは28℃以上であり、好ましくは45℃以下、より好ましくは40℃以下、更に好ましくは38℃以下である。また、茶抽出液のpHは好ましくはpH3.0〜12.5、より好ましくはpH3.5〜10.0、更に好ましくはpH4.0〜7.0である。発酵時間は、発酵温度や試料量に応じて一概には決定されないが、例えば、16〜96時間である。このように茶抽出液をラクトバチルス・ペントーサスに属する菌を用いて発酵させることにより、従来の伝統的な微生物発酵茶である阿波番茶は茶葉を樽漬けして自然発酵させることで10日から3週間程度の調製時間を要するものであったが、大幅な時間短縮が可能となり、生産性が向上することになる。   The fermentation conditions by the bacteria are not particularly limited as long as they are fermented in a tea extract. For example, an additive containing a carbon source, a nitrogen source, inorganic salts, organic nutrients, and the like is added for fermentation. You may let them. Specifically, for example, yeast extract, which is an extract obtained by extracting components in yeast by treatment with enzyme, hot water, or the like, can be added to the tea extract as a nitrogen source. Fermentation temperature becomes like this. Preferably it is 10 degreeC or more, More preferably, it is 15 degreeC or more, More preferably, it is 28 degreeC or more, Preferably it is 45 degrees C or less, More preferably, it is 40 degrees C or less, More preferably, it is 38 degrees C or less. The pH of the tea extract is preferably pH 3.0 to 12.5, more preferably pH 3.5 to 10.0, and still more preferably pH 4.0 to 7.0. The fermentation time is not generally determined according to the fermentation temperature or the sample amount, but is, for example, 16 to 96 hours. By fermenting the tea extract with bacteria belonging to Lactobacillus pentosas in this way, Awaban tea, which is a traditional traditional microbial fermented tea, can be pickled from tea leaves and fermented naturally for 10 to 3 days. Although preparation time of about a week is required, the time can be greatly shortened and productivity is improved.

かくして茶抽出液を前記したラクトバチルス・ペントーサスに属する菌で発酵させることにより、1-(3’,4’,5’-trihydroxyphenyl)-3-(2’’,4’’,6’’-trihydroxyphenyl)-propan-2-olを含有する組成物を得ることができる。   Thus, 1- (3 ', 4', 5'-trihydroxyphenyl) -3- (2 '', 4 '', 6 ''-is obtained by fermenting the tea extract with the bacteria belonging to the aforementioned Lactobacillus pentosas. A composition containing trihydroxyphenyl) -propan-2-ol can be obtained.

得られた発酵カテキン含有組成物における本発明の発酵カテキンの含有量は、茶抽出液や菌の種類、発酵条件、後述するその後の処理条件等によって一概に設定することはできないが、好ましくは0.13mg/mL以上、より好ましくは0.5mg/mL以上、更に好ましくは1.0mg/mL以上である。   The content of the fermented catechin of the present invention in the obtained fermented catechin-containing composition cannot be set unconditionally depending on the type of tea extract or fungus, fermentation conditions, subsequent processing conditions described below, etc., but preferably 0.13 mg / mL or more, more preferably 0.5 mg / mL or more, still more preferably 1.0 mg / mL or more.

また、本発明においては、ラクトバチルス・ペントーサスに属する菌によって、epigallocatechinから本発明の発酵カテキンへの代謝が促進されることから、本発明の発酵カテキン含有組成物中、epigallocatechinと発酵カテキンの含有重量比(epigallocatechin/発酵カテキン)は、好ましくは50/50以下、より好ましくは40/60以下、更に好ましくは30/70以下、更に好ましくは20/80以下、更に好ましくは10/90以下である。また、実質的にepigallocatechinが含有されない程度に代謝が促進されていてもよい。なお、本明細書において、「実質的に含有されない」とは、例えば、後述の実施例に示す測定方法において検出限界以下となるのであればよく、含有量が0.01mg/mL以下のことを言う。   Further, in the present invention, metabolism from epigallocatechin to the fermented catechin of the present invention is promoted by the bacteria belonging to Lactobacillus pentosas, and therefore the weight content of epigallocatechin and fermented catechin in the fermented catechin-containing composition of the present invention The ratio (epigallocatechin / fermented catechin) is preferably 50/50 or less, more preferably 40/60 or less, still more preferably 30/70 or less, still more preferably 20/80 or less, and even more preferably 10/90 or less. Metabolism may be promoted to such an extent that epigallocatechin is not substantially contained. In the present specification, “substantially not contained” means, for example, that the content is 0.01 mg / mL or less as long as it is below the detection limit in the measurement method shown in the Examples below. .

後発酵茶葉は緑茶葉と比較してepigallocatechin-3-O-gallateが顕著に減少していることが知られているが、本発明においてはepigallocatechin-3-O-gallateの減少は比較的緩やかであり、epigallocatechin-3-O-gallateとしての効果も期待できる。本発明の発酵カテキン含有組成物中のepigallocatechin-3-O-gallateの含有量は、好ましくは0.16mg/mL以上、より好ましくは0.5mg/mL以上、更に好ましくは1.0mg/mL以上である。   It is known that post-fermented tea leaves have a significant decrease in epigallocatechin-3-O-gallate compared to green tea leaves, but in the present invention, the decrease in epigallocatechin-3-O-gallate is relatively gradual. Yes, the effect as epigallocatechin-3-O-gallate can be expected. The content of epigallocatechin-3-O-gallate in the fermented catechin-containing composition of the present invention is preferably 0.16 mg / mL or more, more preferably 0.5 mg / mL or more, and further preferably 1.0 mg / mL or more.

また、本発明の発酵カテキン含有組成物中、発酵カテキンとepigallocatechin-3-O-gallateの含有重量比(発酵カテキン/epigallocatechin-3-O-gallate)は、好ましくは20/80以上、より好ましくは40/60以上、更に好ましくは45/55以上である。   In the fermented catechin-containing composition of the present invention, the weight ratio of fermented catechin to epigallocatechin-3-O-gallate (fermented catechin / epigallocatechin-3-O-gallate) is preferably 20/80 or more, more preferably 40/60 or more, more preferably 45/55 or more.

本発明の発酵カテキン含有組成物は、発酵カテキンや前記した化合物以外に、caffeine、gallic acid、epicatechin、epicatechin-3-O-gallate、catechin、gallocatechin、gallocatechin-3-O-gallate、pyrogallolなどを含有してもよい。それらの含有量は、本発明の効果を損なわない範囲内であれば、特に限定されない。なお、本明細書において、式(I)で表される化合物、epigallocatechin-3-O-gallate、epigallocatechin、及びその他の化合物は、後述の実施例に示す測定方法に従って測定することができる。   The fermented catechin-containing composition of the present invention contains caffeine, gallic acid, epicatechin, epicatechin-3-O-gallate, catechin, gallocatechin, gallocatechin-3-O-gallate, pyrogallol, etc. in addition to the fermented catechin and the compounds described above May be. Their content is not particularly limited as long as it does not impair the effects of the present invention. In the present specification, the compound represented by the formula (I), epigallocatechin-3-O-gallate, epigallocatechin, and other compounds can be measured according to the measurement methods described in the examples below.

また、得られる本発明の発酵カテキン含有組成物に対しては、ろ過、遠心分離、濃縮、限外ろ過、凍結乾燥、粉末化、及び分画からなる群より選ばれる1種又は2種以上の処理を、公知の方法に従って行ってもよく、そのまま製剤化したり、飲食品(健康食品)等の原材料に用いることが可能な形態に調製したりしてもよい。よって、本発明の発酵カテキン含有組成物の一態様として前記処理物が含まれる。   In addition, for the obtained fermented catechin-containing composition of the present invention, one or more selected from the group consisting of filtration, centrifugation, concentration, ultrafiltration, lyophilization, powdering, and fractionation The treatment may be performed according to a known method, or may be formulated as it is, or may be prepared in a form that can be used for raw materials such as foods and drinks (health foods). Therefore, the said processed material is contained as one aspect | mode of the fermented catechin containing composition of this invention.

本発明の一態様として、本発明のエネルギー代謝亢進用組成物、交感神経活動亢進用組成物、脂肪燃焼促進用組成物、抗肥満用組成物、又は体温上昇用組成物を飲食品とするものであり、別の一態様として、本発明の製造方法により得られる本発明の発酵カテキン含有組成物を原料とする飲食品である。   As one aspect of the present invention, the composition for enhancing energy metabolism, the composition for enhancing sympathetic nerve activity, the composition for promoting fat burning, the composition for anti-obesity, or the composition for increasing body temperature of the present invention is used as a food or drink. And as another aspect, it is food-drinks which use the fermented catechin containing composition of this invention obtained by the manufacturing method of this invention as a raw material.

本発明の発酵カテキン含有組成物を原料とする飲食品の場合、その製造方法としては、発酵カテキン含有組成物の使用量、添加時期、添加方法は特に限定されず、その他に添加配合される成分も限定なく用いることができ、その使用量や添加方法も公知技術に従って適宜選択することができる。具体的には、例えば、製剤分野や食品分野等において通常使用される担体、基剤、及び/又は添加剤等を本発明の目的を達成する範囲内で適宜配合することができる。また、既製の公知の飲食品に、本発明の発酵カテキン含有組成物を添加して、溶解及び/又は懸濁することで調製してもよい。なお、公知の飲食品が、前記式(I)で表される化合物を元来含有するものであってもよい。   In the case of foods and drinks using the fermented catechin-containing composition of the present invention as a raw material, the production method thereof is not particularly limited, and the amount of addition, addition time, and method of addition of the fermented catechin-containing composition are not limited. Can also be used without limitation, and the amount and method of addition thereof can be appropriately selected according to known techniques. Specifically, for example, carriers, bases, and / or additives that are usually used in the pharmaceutical field, food field, and the like can be appropriately blended within a range that achieves the object of the present invention. Moreover, you may prepare by adding the fermented catechin containing composition of this invention to ready-made known food-drinks, and melt | dissolving and / or suspending. A known food or drink may originally contain the compound represented by the formula (I).

本発明の飲食品において、1-(3’,4’,5’-trihydroxyphenyl)-3-(2’’,4’’,6’’-trihydroxyphenyl)-propan-2-olの含有量は、通常0.00002〜100重量%、好ましくは0.0002〜30重量%、より好ましくは0.002〜5重量%程度である。   In the food and drink of the present invention, the content of 1- (3 ', 4', 5'-trihydroxyphenyl) -3- (2 '', 4 '', 6 ''-trihydroxyphenyl) -propan-2-ol is Usually, it is about 0.00002 to 100% by weight, preferably about 0.0002 to 30% by weight, and more preferably about 0.002 to 5% by weight.

本発明のエネルギー代謝亢進用組成物、交感神経活動亢進用組成物、脂肪燃焼促進用組成物、抗肥満用組成物、又は体温上昇用組成物である飲食品、ならびに、本発明の製造方法により得られる飲食品の形態としては、特に限定はなく、例えば炭酸飲料、天然果汁、果汁飲料、清涼飲料水(果汁入りも含む)、果肉飲料、果粒入り果実食品、野菜系飲料、豆乳・豆乳飲料、コーヒー飲料、お茶飲料、ゼリー飲料、粉末飲料、濃縮飲料、スポーツ飲料、栄養飲料、アルコール飲料等の嗜好飲料類、栄養食品、サプリメント、丸剤、ハードカプセル剤、ソフトカプセル剤、錠剤〔素錠、糖衣錠、口腔内速崩壊錠、咀嚼可能錠(チュアブル錠)、発泡錠、トローチ剤、フィルムコーティング錠等を含む〕等を例示できる。なお、これらは、既成の飲食品に対して本発明の発酵カテキン含有組成物を調製時又は調製後に添加させたものであればよく、添加時期や添加方法については特に限定されるものではない。   According to the composition for enhancing energy metabolism, the composition for enhancing sympathetic activity, the composition for promoting fat burning, the composition for anti-obesity, or the composition for increasing body temperature of the present invention, and the production method of the present invention. The form of the obtained food or drink is not particularly limited. For example, carbonated drink, natural fruit juice, fruit juice drink, soft drink (including fruit juice), fruit drink, fruit food with fruit granules, vegetable drink, soy milk / soy milk Beverages, coffee beverages, tea beverages, jelly beverages, powdered beverages, concentrated beverages, sports beverages, nutritional beverages, alcoholic beverages and other favorite beverages, nutritional foods, supplements, pills, hard capsules, soft capsules, tablets (plain tablets, Sugar-coated tablets, intraoral quick disintegrating tablets, chewable tablets (chewable tablets), effervescent tablets, troches, film-coated tablets, etc.). In addition, these should just add the fermented catechin containing composition of this invention to the existing food-drinks at the time of preparation or after preparation, and it does not specifically limit about an addition time and the addition method.

本発明の製造方法により得られる飲食品は、本発明のエネルギー代謝亢進用組成物、交感神経活動亢進用組成物、脂肪燃焼促進用組成物、抗肥満用組成物、又は体温上昇用組成物である飲食品と同様に、式(I)で表される化合物を含有する。よって、本発明の製造方法により得られる飲食品は、交感神経活動を亢進させ、例えば、エネルギー代謝の亢進作用、脂肪燃焼の促進作用、体重増加の抑制あるいは体重減少作用、体温の上昇作用等の生理作用を奏することが可能なことから、その目的に応じて、本発明の製造方法により得られる飲食品は、エネルギー代謝亢進用組成物、交感神経活動亢進用組成物、脂肪燃焼促進用組成物、抗肥満用組成物、体温上昇用組成物として用いることができる。従って、本発明はまた、本発明の飲食品の製造方法により得られる飲食品として、本発明の発酵カテキン含有組成物を含有してなる飲食品を提供する。なお、本明細書において、「エネルギー代謝」とはATPがADPに変換されるときに遊離するエネルギーを筋収縮、神経伝達、物質構成、体温調節などに変換する過程のことを意味し、酸素消費量および二酸化炭素排出量からエネルギー消費量として算出される。「交感神経」とは熱産生組織である褐色脂肪組織における交感神経を意味し、交感神経活動が亢進されるとエネルギー代謝が亢進し、体温上昇、脂肪燃焼、ひいては抗肥満などにつながる。「脂肪燃焼」とは酸素消費量に対する二酸化炭素排出量の体積比である呼吸商を指標にしており、呼吸商が低下するほど脂肪を燃焼していることを意味する。「抗肥満」とは体重の増加が抑制されること又は体重が減少することを意味する。   The food or drink obtained by the production method of the present invention is the composition for enhancing energy metabolism, the composition for enhancing sympathetic nerve activity, the composition for promoting fat burning, the composition for anti-obesity, or the composition for increasing body temperature of the present invention. As with certain foods and drinks, it contains a compound represented by the formula (I). Therefore, the food and drink obtained by the production method of the present invention enhances sympathetic nerve activity, such as an energy metabolism enhancing action, a fat burning promoting action, a weight gain inhibiting or weight reducing action, a body temperature raising action, etc. According to the purpose, foods and beverages obtained by the production method of the present invention include a composition for enhancing energy metabolism, a composition for enhancing sympathetic nerve activity, and a composition for promoting fat burning. It can be used as an anti-obesity composition or a body temperature raising composition. Therefore, this invention also provides the food / beverage products containing the fermented catechin containing composition of this invention as food / beverage products obtained by the manufacturing method of the food / beverage products of this invention. In this specification, “energy metabolism” means the process of converting energy released when ATP is converted to ADP into muscle contraction, nerve transmission, substance composition, body temperature regulation, etc., and oxygen consumption. It is calculated as energy consumption from the amount and carbon dioxide emission. “Sympathetic nerve” means a sympathetic nerve in brown adipose tissue, which is a heat-producing tissue. When sympathetic nerve activity is increased, energy metabolism is increased, leading to increased body temperature, fat burning, and anti-obesity. “Fat burning” is based on the respiratory quotient, which is the volume ratio of the carbon dioxide emission to the oxygen consumption, and means that fat is burned as the respiratory quotient decreases. “Anti-obesity” means that weight gain is suppressed or weight is decreased.

本発明の製造方法により得られる飲食品は、本発明のエネルギー代謝亢進用組成物、交感神経活動亢進用組成物、脂肪燃焼促進用組成物、抗肥満用組成物、又は体温上昇用組成物である飲食品と同様に、例えば、エネルギー代謝の亢進作用、体温の上昇作用、脂肪の燃焼作用、抗肥満作用の発揮を要する症状に好適に使用される。具体的には、例えば、体温上昇、冷え性改善、抗肥満、内臓脂肪低減、美容、新陳代謝促進、免疫賦活、抗疲労、抗鬱等に好適に用いられる。   The food or drink obtained by the production method of the present invention is the composition for enhancing energy metabolism, the composition for enhancing sympathetic nerve activity, the composition for promoting fat burning, the composition for anti-obesity, or the composition for increasing body temperature of the present invention. Like certain foods and drinks, for example, it is suitably used for symptoms that require an action of enhancing energy metabolism, an action of raising body temperature, an action of burning fat, and an anti-obesity action. Specifically, for example, it is suitably used for body temperature increase, cooling improvement, anti-obesity, visceral fat reduction, beauty, promotion of metabolism, immune activation, anti-fatigue, antidepressant and the like.

また、本発明のエネルギー代謝亢進用組成物、交感神経活動亢進用組成物、脂肪燃焼促進用組成物、抗肥満用組成物、又は体温上昇用組成物である飲食品、ならびに、本発明の製造方法により得られる飲食品は、交感神経活動の亢進作用を有することにより、エネルギー代謝の亢進作用、体温の上昇作用、脂肪の燃焼作用、ひいては抗肥満作用の発揮を要する症状の改善、予防に極めて有用である。すなわち、本発明のエネルギー代謝亢進用組成物、交感神経活動亢進用組成物、脂肪燃焼促進用組成物、抗肥満用組成物、又は体温上昇用組成物である飲食品、ならびに、本発明の製造方法により得られる飲食品は、上記症状の予防又は改善を目的とすることを付した保健機能食品や健康食品として、あるいは1-(3’,4’,5’-trihydroxyphenyl)-3-(2’’,4’’,6’’-trihydroxyphenyl)-propan-2-olの有する機能に関する機能性表示を付した食品として、例えば、エネルギー代謝の亢進を必要とする個体だけでなく、エネルギー代謝は低くはないが、体重の上昇を抑制する必要のある個体、冷えを抑制する必要のある個体、内臓脂肪の増加を抑制する必要のある個体、新陳代謝の低下を抑制する必要のある個体、風邪を治療又は予防したい個体、美容の維持を必要とする個体、疲れを抑制する必要のある個体等にとって極めて有用な組成物となる。   In addition, the composition for enhancing energy metabolism, the composition for enhancing sympathetic nerve activity, the composition for promoting fat burning, the composition for anti-obesity, or the composition for increasing body temperature of the present invention, and the production of the present invention The food and drink obtained by the method has an action of enhancing sympathetic nerve activity, which is extremely effective in improving and preventing symptoms that require an action of enhancing energy metabolism, an action of raising body temperature, an action of burning fat, and an anti-obesity action. Useful. That is, the composition for enhancing energy metabolism, the composition for enhancing sympathetic nerve activity, the composition for promoting fat burning, the composition for anti-obesity, or the composition for increasing body temperature of the present invention, and the production of the present invention The food or drink obtained by the method is used as a health functional food or health food with the purpose of preventing or improving the above symptoms, or 1- (3 ', 4', 5'-trihydroxyphenyl) -3- (2 ``, 4 '', 6 ''-trihydroxyphenyl) -propan-2-ol is a food with a functional label regarding the functions of, for example, not only individuals who need increased energy metabolism but also energy metabolism. Although not low, individuals who need to suppress weight gain, individuals who need to control coldness, individuals who need to suppress the increase in visceral fat, individuals who need to suppress a decrease in metabolism, colds Individuals who want to treat or prevent, need to maintain beauty A very useful composition for individuals such individuals, that need suppress fatigue to.

本発明のエネルギー代謝亢進用組成物、交感神経活動亢進用組成物、脂肪燃焼促進用組成物、抗肥満用組成物、又は体温上昇用組成物である飲食品、ならびに、本発明の製造方法により得られる飲食品はその用途を表示できるとする。表示の内容としては、例えば乳酸菌発酵処理物又は1-(3’,4’,5’-trihydroxyphenyl)-3-(2’’,4’’,6’’-trihydroxyphenyl)-propan-2-olの有する機能に由来する用途を挙げることができる。当該表示は、飲食品自体に付されてもよいし、飲食品の容器又は包装に付されていてもよい。   According to the composition for enhancing energy metabolism, the composition for enhancing sympathetic activity, the composition for promoting fat burning, the composition for anti-obesity, or the composition for increasing body temperature of the present invention, and the production method of the present invention. It is assumed that the obtained food or drink can display its use. Examples of the content of the indication include, for example, lactic acid bacteria fermented product or 1- (3 ', 4', 5'-trihydroxyphenyl) -3- (2 '', 4 '', 6 ''-trihydroxyphenyl) -propan-2-ol The use derived from the function which has can be mentioned. The said display may be attached | subjected to food / beverage products itself, and may be attached | subjected to the container or packaging of food / beverage products.

本発明のエネルギー代謝亢進用組成物、交感神経活動亢進用組成物、脂肪燃焼促進用組成物、抗肥満用組成物、又は体温上昇用組成物である飲食品、ならびに、本発明の製造方法により得られる飲食品の摂取量は、それらの形態、摂取方法、摂取目的、及び当該飲食品の摂取対象であるヒトの年齢、体重、症状によって適宜設定され一定ではないが、例えば、、1-(3’,4’,5’-trihydroxyphenyl)-3-(2’’,4’’,6’’-trihydroxyphenyl)-propan-2-ol量が体重50kgのヒトで1日当たり、好ましくは1mg〜10g、より好ましくは10mg〜3g、さらに好ましくは100mg〜1g程度となる量において、適宜設定することができる。また、所望の摂取量範囲内において、1日内において単回で又は複数回で使用してもよく、使用時間も期間も任意である。   According to the composition for enhancing energy metabolism, the composition for enhancing sympathetic activity, the composition for promoting fat burning, the composition for anti-obesity, or the composition for increasing body temperature of the present invention, and the production method of the present invention. The intake of the obtained food or drink is not set and is appropriately determined depending on the form, intake method, purpose of intake, and the age, weight, and symptom of the person who is the intake of the food or drink. 3 ', 4', 5'-trihydroxyphenyl) -3- (2 '', 4 '', 6 ''-trihydroxyphenyl) -propan-2-ol in a human with a body weight of 50 kg per day, preferably 1 mg to 10 g More preferably, the amount can be appropriately set in an amount of about 10 mg to 3 g, more preferably about 100 mg to 1 g. Further, it may be used once or multiple times within a day within a desired intake range, and the use time and period are arbitrary.

以下、実施例を示して本発明を具体的に説明するが、本発明は下記実施例に制限されるものではない。   EXAMPLES Hereinafter, although an Example is shown and this invention is demonstrated concretely, this invention is not restrict | limited to the following Example.

実施例1
TUA4337L株を用いて茶エキスを発酵させて1-(3’,4’,5’-trihydroxyphenyl)-3-(2’’,4’’,6’’-trihydroxyphenyl)-propan-2-olを生成させた。具体的には、以下の通りである。なお、1-(3’,4’,5’-trihydroxyphenyl)-3-(2’’,4’’,6’’-trihydroxyphenyl)-propan-2-olのことを発酵カテキンと記載する。
<発酵手順>
(1)TUA4337LをグリセロールストックからMRS(10mL)へ1v/v%植菌
(2)培養(30℃、20hr)
(3)遠心(8,000rpm、5min、4℃)後、上清除去
(4)培養液と同量の滅菌水で洗浄(×2回)
(5)滅菌水を用いてOD660=10になるよう菌液を調製
(6)茶パウダー(カーギルジャパン社製)を滅菌水に10w/v%添加し懸濁した後の遠心(8,000rpm、5min)後の上清(Bx 11.9)に、酵母エキス(BD社製)を0、0.04、0.2、1w/v%添加し、(5)で調製した菌液を1v/v%添加
(7)培養(35℃)
Example 1
Fermented tea extract using TUA4337L strain to give 1- (3 ', 4', 5'-trihydroxyphenyl) -3- (2 '', 4 '', 6 ''-trihydroxyphenyl) -propan-2-ol Generated. Specifically, it is as follows. In addition, 1- (3 ′, 4 ′, 5′-trihydroxyphenyl) -3- (2 ″, 4 ″, 6 ″ -trihydroxyphenyl) -propan-2-ol is referred to as fermentation catechin.
<Fermentation procedure>
(1) 1% v / v inoculation of TUA4337L from glycerol stock to MRS (10mL) (2) Culture (30 ℃, 20hr)
(3) After centrifugation (8,000rpm, 5min, 4 ℃), remove supernatant (4) Wash with sterilized water in the same volume as the culture solution (× 2)
(5) Prepare bacterial solution using sterilized water so that OD 660 = 10. (6) Centrifugation after adding 10w / v% tea powder (Cargill Japan) to sterilized water and suspending (8,000rpm, 5 min), 0, 0.04, 0.2, 1 w / v% of yeast extract (BD) is added to the supernatant (Bx 11.9), and 1 v / v% of the bacterial solution prepared in (5) is added (7) Culture (35 ℃)

得られた培養液を、純水で希釈して更に40%アセトニトリルで2倍希釈後、0.45μmのフィルターで処理して、以下の分析に供した。HPLCの代表的なチャートを図1に、発酵カテキンの生成結果を図2に示す。
<HPLC分析条件>
カラム:capcell pak C18, 4.6mmφ×150mm、5μm(資生堂社製)
移動相:A 0.05% TFA/H2O、B 90% CH3CN, 0.05% TFA/H2O
グラジエント:B 5→35v/v%(0→13min)、B 35→70v/v%(13→20min)、B 70v/v%(20→25min)
流速:1.0mL/min
検出:A225nm
注入量:10μL
The obtained culture broth was diluted with pure water, further diluted 2-fold with 40% acetonitrile, treated with a 0.45 μm filter, and subjected to the following analysis. A typical HPLC chart is shown in FIG. 1, and the production results of fermented catechins are shown in FIG.
<HPLC analysis conditions>
Column: capcell pak C18, 4.6mmφ × 150mm, 5μm (Shiseido)
Mobile phase: A 0.05% TFA / H 2 O, B 90% CH 3 CN, 0.05% TFA / H 2 O
Gradient: B 5 → 35v / v% (0 → 13min), B 35 → 70v / v% (13 → 20min), B 70v / v% (20 → 25min)
Flow rate: 1.0mL / min
Detection: A225nm
Injection volume: 10μL

図1及び2より、TUA4337Lを用いてお茶エキスを発酵させることにより、経時的にepigallocatechin(EGC)が減少し、発酵カテキンが生成した。また酵母エキスを添加することにより、生成速度が速まった。なお、図1におけるCの新規ピークが発酵カテキンであることはNMRにより確認した。   As shown in FIGS. 1 and 2, when tea extract was fermented using TUA4337L, epigallocatechin (EGC) decreased with time, and fermented catechin was produced. Moreover, the production | generation rate accelerated by adding yeast extract. In addition, it confirmed by NMR that the new peak of C in FIG. 1 was fermentation catechin.

実施例2
乳酸菌に属する種々の株による発酵カテキンの生成の検討を行った。
Example 2
The production of fermented catechins by various strains belonging to lactic acid bacteria was examined.

乳酸菌として様々なL. pentosusおよびL. plantarumの菌株を用いて発酵カテキンの生産性をJCM基準株と共に検討した。L. pentosusとして、TUA4337L、AF43、AF48、AF51、AF64、JCM基準株1558Tを、L. plantarumとしてはAF70、AF71、AF62、AF63、JCM基準株1149Tを検討した。これらの乳酸菌を用いて、実施例1と同様の手順で発酵カテキンの生産性を評価した(酵母エキスを0 w/v%および1 w/v% 添加したお茶エキスにて検討した)。具体的には、72時間培養した後の培養液中の発酵カテキンの濃度を定量した。結果を図3に示す。   Using various strains of L. pentosus and L. plantarum as lactic acid bacteria, the productivity of fermented catechins was examined together with the JCM reference strain. As L. pentosus, TUA4337L, AF43, AF48, AF51, AF64 and JCM standard strain 1558T were examined, and as L. plantarum, AF70, AF71, AF62, AF63 and JCM standard strain 1149T were examined. Using these lactic acid bacteria, productivity of fermented catechin was evaluated in the same procedure as in Example 1 (examined with tea extract supplemented with 0 w / v% and 1 w / v% yeast extract). Specifically, the concentration of fermented catechin in the culture solution after culturing for 72 hours was quantified. The results are shown in FIG.

図3より、L. pentosusは菌株によらず発酵カテキンを生成したが、一方でL. plantarumはいずれの菌株においても発酵カテキンを生成することが出来なかった。   From FIG. 3, L. pentosus produced fermented catechins regardless of the strain, whereas L. plantarum was unable to produce fermented catechins in any strain.

実施例3
実施例1で得られた発酵カテキンによる褐色脂肪組織の交感神経活動亢進作用の検討を行った。なお、実施例1で得られた発酵カテキンとは、実施例1における培養液から発酵カテキンのピーク画分を単離して濃縮後、凍結乾燥により析出させたものである。
Example 3
The effect of fermented catechin obtained in Example 1 on sympathetic nerve activity in brown adipose tissue was examined. The fermented catechin obtained in Example 1 is a product obtained by isolating and concentrating the peak fraction of fermented catechin from the culture solution in Example 1 and then precipitating it by lyophilization.

具体的には、実験には12時間毎の明暗周期下(8時より12時間点灯)で1週間飼育した体重約300gのWistar系雄性ラット(約9週齢、各群n=3)を3時間絶食させてウレタン麻酔し、十二指腸投与用のカニューレを挿入し、その後、肩甲間褐色脂肪組織の交感神経の遠心枝を銀電極で吊り上げ、その神経の電気活動を測定した。この神経の測定値が落着いた時期(13時頃)に、各試験サンプル1mL(コントロール:滅菌水、発酵カテキン:1μg/mL水分散液)をカニューレにて十二指腸投与し、褐色脂肪組織の交感神経活動の変化を電気生理学的に測定した。結果を図4に示す。   Specifically, in the experiment, 3 Wistar male rats (approx. 9 weeks old, n = 3 for each group) with a body weight of about 300 g were bred for 1 week under a light / dark cycle every 12 hours (lighted for 12 hours from 8 o'clock). After fasting for anesthesia and urethane anesthesia, a cannula for duodenal administration was inserted, and then the sympathetic nerve branch of the interscapular brown adipose tissue was lifted with a silver electrode, and the electrical activity of the nerve was measured. At the time when the measurement value of this nerve settled (around 13:00), 1 mL of each test sample (control: sterilized water, fermented catechin: 1 μg / mL aqueous dispersion) was cannulated into the duodenum and sympathetic nerves in brown adipose tissue Changes in activity were measured electrophysiologically. The results are shown in FIG.

図4より、BAT-SNA値において、発酵カテキンはコントロールと比較すると有意な上昇が見らた。したがって発酵カテキンは褐色脂肪組織における交感神活動を亢進させると考えられた。また、この交感神経活動の亢進は、エネルギー代謝を亢進させるメカニズムになっていることが考えられたため、以下にその実証を行なった。   FIG. 4 shows that the fermentation catechin significantly increased in the BAT-SNA value compared to the control. Thus, fermented catechins were thought to enhance sympathetic activity in brown adipose tissue. Moreover, since it was thought that this enhancement of sympathetic nerve activity is a mechanism for enhancing energy metabolism, the following was demonstrated.

実施例4
実施例1で得られた発酵カテキンによるエネルギー代謝亢進作用及び脂肪燃焼促進作用の検討を行った。なお、発酵カテキンは実施例3と同様に調製したものを用いた。
Example 4
The effect of enhancing energy metabolism and promoting fat burning by the fermented catechin obtained in Example 1 was examined. The fermented catechin used was prepared in the same manner as in Example 3.

具体的には、C57BL/6Jマウス(7週齢、雄)において滅菌水250μLの経口投与を5日間続け、経口投与に慣れさせた。その後、体重の平均値に差が出ないようコントロール群と発酵カテキン群に群分けした(各n=4)。エネルギー代謝測定装置(オキシマックス、バイオリサーチセンター社)のチャンバーにマウスを2日間入れて環境に慣れさせた後に、餌を高脂肪食(60kcal%FAT、Research Diet社)に切り替え、各マウスの酸素消費量(VO2 (mL/kg/hr))および排出二酸化炭素排出量(VCO2(mL/kg/hr))の測定を開始した。各マウスには1日あたり試験サンプル250μL(コントロール:滅菌水、発酵カテキン:5mg/mL水分散液)を経口投与し、11日間の投与を続けた。消費カロリーおよび呼吸商は以下計算式により算出した。
消費カロリー:VO2 ×(RER×1.232+3.815)/1000
ここで、RQ (呼吸商)=VCO2/ VO2
Specifically, oral administration of 250 μL of sterile water was continued for 5 days in C57BL / 6J mice (7 weeks old, male), and they were accustomed to oral administration. Then, it divided into the control group and the fermentation catechin group so that a difference might not appear in the average value of a body weight (each n = 4). After putting the mouse in the chamber of the energy metabolism measuring device (Oxymax, Bioresearch Center) and getting used to the environment for 2 days, the diet was switched to a high fat diet (60 kcal% FAT, Research Diet) and the oxygen in each mouse Measurement of consumption (VO 2 (mL / kg / hr)) and emission carbon dioxide emission (VCO 2 (mL / kg / hr)) was started. Each mouse was orally administered 250 μL of test sample per day (control: sterile water, fermented catechin: 5 mg / mL aqueous dispersion) and continued administration for 11 days. The calorie consumption and the respiratory quotient were calculated by the following formula.
Calories burned: VO 2 x (RER x 1.232 + 3.815) / 1000
Where RQ (breathing quotient) = VCO 2 / VO 2

発酵カテキンを投与することにより、コントロール群と比較して、消費カロリーの増加が見られた。11日までの消費カロリーを比較したが、投与前と4日目のデータを図5に示す。これは明期(安静期:AM7:00〜PM19:00)の消費カロリーを解析した結果であり、発酵カテキン群で有意に消費カロリーが増加していた。これは安静期での効果であるため、発酵カテキンにより基礎代謝が向上したことを示していると考えられ、エネルギー代謝亢進作用があることが確認された。また、発酵カテキンの投与前後での脂肪燃焼効果の変化を検証するために、呼吸商の測定を行なった。呼吸商とは、ある時間において生体内で栄養素が分解されてエネルギーに変換するまでの酸素消費量に対する二酸化炭素排出量の体積比のことである。体内でどのような割合で栄養素が燃焼しているのかという概要理解の指標として広く用いられている。つまり、呼吸商は消費したエネルギー源を反映し、一般に最も呼吸商が高値を示すのは糖質(RQ=1.0)であり、最も低値を示すのは脂質(RQ≒0.7)である。すなわち脂肪を多く燃焼させた時には酸素の消費量に対して二酸化炭素の排出量が少なく、呼吸商の値が減少する。この値が低いほど、脂肪燃焼されていることを示し、脂肪燃焼効果が高いと考えられる。図6には投与前、投与11日目の呼吸商の差異を示すが、コントロール群と比較し、発酵カテキンを投与した場合に呼吸商がより低下しており、脂肪燃焼効果が促進されると考えられる。   By administration of fermented catechins, an increase in calorie consumption was seen compared to the control group. The calorie consumption up to the 11th day was compared, and the data before administration and on the 4th day are shown in FIG. This is a result of analyzing calorie consumption in the light period (resting period: AM 7:00 to PM 19:00), and calorie consumption was significantly increased in the fermented catechin group. Since this is an effect in the resting period, it was considered that basal metabolism was improved by fermented catechin, and it was confirmed that there was an action of promoting energy metabolism. Moreover, in order to verify the change of the fat burning effect before and after administration of fermented catechin, the respiratory quotient was measured. The respiratory quotient is a volume ratio of carbon dioxide emission to oxygen consumption until nutrients are decomposed in vivo and converted into energy. It is widely used as an index for understanding the outline of how much nutrients are burned in the body. In other words, the respiratory quotient reflects the energy source consumed. In general, the highest quotient is the carbohydrate (RQ = 1.0), and the lowest is the lipid (RQ≈0.7). That is, when a large amount of fat is burned, the amount of carbon dioxide emitted is less than the amount of oxygen consumed, and the value of the respiratory quotient decreases. The lower this value, the more fat is burned, and the higher the fat burning effect. FIG. 6 shows the difference in respiratory quotient before administration and on the 11th day after administration, but compared to the control group, the respiratory quotient is lower when fermented catechin is administered, and the fat burning effect is promoted. Conceivable.

実施例5
実施例1で得られた発酵カテキンによる体温上昇作用の検討を行った。なお、発酵カテキンは実施例3と同様に調製したものを用いた。
Example 5
The body temperature increasing action by the fermented catechin obtained in Example 1 was examined. The fermented catechin used was prepared in the same manner as in Example 3.

具体的には、2週間の間、高脂肪食(60kcal%FAT)で飼育したC57BL/6Jマウス(10週齢、雄)に、1日あたり試験サンプル250μL(コントロール:滅菌水、発酵カテキン:1.6mg/mL水分散液)を経口投与した(各n=11〜12)。経口投与から5分及び60分後に、マイクロプローブサーモメータ(BAT-12、muromachi社)を用いて直腸温をそれぞれ測定し、直腸温の変化幅を算出した。結果を図7に示す。   Specifically, C57BL / 6J mice (10 weeks old, male) bred on a high fat diet (60 kcal% FAT) for 2 weeks were tested with 250 μL of test sample per day (control: sterile water, fermented catechin: 1.6 mg / mL aqueous dispersion) was orally administered (each n = 11 to 12). Five minutes and 60 minutes after oral administration, rectal temperature was measured using a microprobe thermometer (BAT-12, muromachi), and the change width of rectal temperature was calculated. The results are shown in FIG.

図7より、発酵カテキンはコントロールに対して有意に直腸温を上昇させた。したがって、発酵カテキンは体温上昇作用を有すると考えられる。   From FIG. 7, fermented catechin significantly increased the rectal temperature relative to the control. Therefore, it is considered that fermented catechin has an effect of increasing body temperature.

実施例6
実施例1で得られた発酵カテキンによる抗肥満作用の検討を行った。なお、発酵カテキンは実施例3と同様に調製したものを用いた。
Example 6
The anti-obesity action by the fermented catechin obtained in Example 1 was examined. The fermented catechin used was prepared in the same manner as in Example 3.

具体的には、C57BL/6Jマウス(7週齢、雄)を2週間の間、高脂肪食(60kcal%FAT)で飼育した。その間、滅菌水250μLの経口投与を5日間続け、経口投与に慣れさせた。その後、体重の平均値に差が出ないようコントロール群と発酵カテキン投与群に群分けした(各n=4)。各マウスには1日あたり試験サンプル250μL(コントロール:滅菌水、発酵カテキン:5mg/mL水分散液)を経口投与し、経時的に体重測定を行った。体重増加の推移を図8に示す。   Specifically, C57BL / 6J mice (7 weeks old, male) were bred on a high fat diet (60 kcal% FAT) for 2 weeks. Meanwhile, oral administration of 250 μL of sterilized water was continued for 5 days to accustom them to oral administration. Then, it divided into the control group and the fermentation catechin administration group so that a difference might not appear in the average value of a body weight (each n = 4). Each mouse was orally administered 250 μL of test sample per day (control: sterile water, fermented catechin: 5 mg / mL aqueous dispersion), and body weight was measured over time. The change in weight gain is shown in FIG.

図8より、発酵カテキンを投与することにより体重増加が抑えられる傾向が認められ、発酵カテキンは抗肥満作用を有すると考えられる。この作用メカニズムとしては、体温上昇効果と同様にエネルギー代謝亢進作用が考えられる。   From FIG. 8, the tendency to suppress weight gain is recognized by administering fermented catechins, and fermented catechins are considered to have an anti-obesity effect. As this action mechanism, the action of promoting energy metabolism is considered as well as the effect of increasing body temperature.

以下、本発明の組成物の具体的処方を例示する。これらの組成物は公知の方法に従って調製することができる。   Hereinafter, specific formulations of the composition of the present invention will be exemplified. These compositions can be prepared according to known methods.

処方例:緑茶飲料1
実施例1の培養液を乾燥後、9倍量のデキストリンと混合し発酵カテキン混合物を調製し、上記混合物および粉末茶に水に加えて混合後、121℃、20分間滅菌して緑茶飲料を調製する。
Formulation example: Green tea beverage 1
The culture broth of Example 1 was dried and then mixed with 9 times the amount of dextrin to prepare a fermented catechin mixture. After adding the above mixture and powdered tea to water and mixing, sterilized at 121 ° C. for 20 minutes to prepare a green tea beverage To do.

処方例:コーヒー飲料
コーヒー豆(L値:27)200gに約10重量倍の沸騰水を加えてBx.2.6のコーヒー抽出液2000gを得る。この抽出液に、上記緑茶飲料の際に調製した混合物、グラニュー糖、牛乳、pH調整剤を混合してコーヒー飲料を調製する。
Formulation example: coffee drink About 10 times weight of boiling water is added to 200 g of coffee beans (L value: 27), and Bx. Obtain 2000 g of 2.6 coffee extract. A coffee beverage is prepared by mixing this extract with the mixture prepared at the time of the green tea beverage, granulated sugar, milk, and a pH adjuster.

処方例:炭酸飲料
上記緑茶飲料の際に調製した混合物を水に溶解した後、リン酸を用いてpHを3.8に調整し、酸化防止剤、香料、酸味料、甘味料、カラメル色素を各々適量加えて約24時間貯蔵する。その間、炭酸ガスを適量添加し、その後、濾過・瓶詰め・殺菌(65℃以上で10分間加熱)の工程を経て、炭酸飲料を得る。
Formulation example: carbonated beverage After the mixture prepared in the above green tea beverage was dissolved in water, the pH was adjusted to 3.8 using phosphoric acid, and an antioxidant, a fragrance, a sour agent, a sweetener, and a caramel color were added. Appropriate amounts of each are added and stored for about 24 hours. Meanwhile, an appropriate amount of carbon dioxide gas is added, and then a carbonated beverage is obtained through the steps of filtration, bottling and sterilization (heating at 65 ° C. or higher for 10 minutes).

処方例:緑茶飲料2
実施例1の培養液から発酵カテキンを単離、乾燥後、9倍量のデキストリンと混合し発酵カテキン混合物を調製し、上記混合物および粉末茶に水に加えて混合後、121℃、20分間滅菌して緑茶飲料を調製する。
Formulation example: Green tea beverage 2
Fermented catechin was isolated from the culture solution of Example 1, dried, then mixed with 9 times the amount of dextrin to prepare a fermented catechin mixture, added to water to the above mixture and powdered tea, mixed and then sterilized at 121 ° C for 20 minutes To prepare a green tea beverage.

従って、本発明には、以下の態様も含まれる。
〔1〕 1-(3’,4’,5’-trihydroxyphenyl)-3-(2’’,4’’,6’’-trihydroxyphenyl)-propan-2-olを有効成分とするエネルギー代謝亢進剤。
〔2〕 1-(3’,4’,5’-trihydroxyphenyl)-3-(2’’,4’’,6’’-trihydroxyphenyl)-propan-2-olを含有する組成物を有効成分とするエネルギー代謝亢進剤。
〔3〕 1-(3’,4’,5’-trihydroxyphenyl)-3-(2’’,4’’,6’’-trihydroxyphenyl)-propan-2-olを有効成分とする交感神経活動亢進剤。
〔4〕 1-(3’,4’,5’-trihydroxyphenyl)-3-(2’’,4’’,6’’-trihydroxyphenyl)-propan-2-olを含有する組成物を有効成分とする交感神経活動亢進剤。
〔5〕 1-(3’,4’,5’-trihydroxyphenyl)-3-(2’’,4’’,6’’-trihydroxyphenyl)-propan-2-olを有効成分とする脂肪燃焼促進剤。
〔6〕 1-(3’,4’,5’-trihydroxyphenyl)-3-(2’’,4’’,6’’-trihydroxyphenyl)-propan-2-olを含有する組成物を有効成分とする脂肪燃焼促進剤。
〔7〕 1-(3’,4’,5’-trihydroxyphenyl)-3-(2’’,4’’,6’’-trihydroxyphenyl)-propan-2-olを有効成分とする抗肥満剤。
〔8〕 1-(3’,4’,5’-trihydroxyphenyl)-3-(2’’,4’’,6’’-trihydroxyphenyl)-propan-2-olを含有する組成物を有効成分とする抗肥満剤。
〔9〕 1-(3’,4’,5’-trihydroxyphenyl)-3-(2’’,4’’,6’’-trihydroxyphenyl)-propan-2-olを有効成分とする体温上昇剤。
〔10〕 1-(3’,4’,5’-trihydroxyphenyl)-3-(2’’,4’’,6’’-trihydroxyphenyl)-propan-2-olを含有する組成物を有効成分とする体温上昇剤。
Therefore, the following aspects are also included in the present invention.
[1] Energy metabolism enhancer containing 1- (3 ', 4', 5'-trihydroxyphenyl) -3- (2``, 4 '', 6 ''-trihydroxyphenyl) -propan-2-ol as an active ingredient .
[2] A composition containing 1- (3 ', 4', 5'-trihydroxyphenyl) -3- (2 '', 4 '', 6 ''-trihydroxyphenyl) -propan-2-ol as an active ingredient Energy metabolism enhancer.
[3] Increased sympathetic nerve activity with 1- (3 ', 4', 5'-trihydroxyphenyl) -3- (2 '', 4 '', 6 ''-trihydroxyphenyl) -propan-2-ol as an active ingredient Agent.
[4] A composition containing 1- (3 ', 4', 5'-trihydroxyphenyl) -3- (2 '', 4 '', 6 ''-trihydroxyphenyl) -propan-2-ol as an active ingredient A sympathetic nerve activity enhancer.
[5] Fat burning accelerator containing 1- (3 ', 4', 5'-trihydroxyphenyl) -3- (2 '', 4 '', 6 ''-trihydroxyphenyl) -propan-2-ol as an active ingredient .
[6] A composition containing 1- (3 ', 4', 5'-trihydroxyphenyl) -3- (2 '', 4 '', 6 ''-trihydroxyphenyl) -propan-2-ol as an active ingredient Fat burning accelerator.
[7] An anti-obesity agent containing 1- (3 ′, 4 ′, 5′-trihydroxyphenyl) -3- (2 ″, 4 ″, 6 ″ -trihydroxyphenyl) -propan-2-ol as an active ingredient.
[8] A composition containing 1- (3 ′, 4 ′, 5′-trihydroxyphenyl) -3- (2 ″, 4 ″, 6 ″ -trihydroxyphenyl) -propan-2-ol as an active ingredient Anti-obesity agent.
[9] A body temperature increasing agent containing 1- (3 ′, 4 ′, 5′-trihydroxyphenyl) -3- (2 ″, 4 ″, 6 ″ -trihydroxyphenyl) -propan-2-ol as an active ingredient.
[10] A composition containing 1- (3 ′, 4 ′, 5′-trihydroxyphenyl) -3- (2 ″, 4 ″, 6 ″ -trihydroxyphenyl) -propan-2-ol as an active ingredient To raise body temperature.

本発明のエネルギー代謝亢進用組成物、交感神経活動亢進用組成物、脂肪燃焼促進用組成物、抗肥満用組成物、体温上昇用組成物は、優れたエネルギー代謝の亢進作用、交感神経活動の亢進作用、脂肪の燃焼促進作用、抗肥満(体重増加の抑制又は体重の減少)作用、体温の上昇作用を有するものであり、例えば、体温上昇、冷え性改善、抗肥満、内臓脂肪低減、美容、新陳代謝促進、免疫賦活、抗疲労、抗鬱等の効果が期待できる。また、本発明の製造方法により得られる1-(3’,4’,5’-trihydroxyphenyl)-3-(2’’,4’’,6’’-trihydroxyphenyl)-propan-2-ol含有組成物は、優れたエネルギー代謝の亢進作用、交感神経活動の亢進作用、脂肪の燃焼促進作用、体重増加の抑制又は体重の減少作用、体温の上昇作用を有するものであり、例えば、体温上昇、冷え性改善、抗肥満、内臓脂肪低減、美容、新陳代謝促進、免疫賦活、抗疲労、抗鬱等の効果が期待できる。   The composition for enhancing energy metabolism, the composition for enhancing sympathetic nerve activity, the composition for promoting fat burning, the composition for anti-obesity, and the composition for increasing body temperature according to the present invention have an excellent energy metabolism enhancing action and sympathetic nerve activity. It has an enhancing action, a fat burning promoting action, an anti-obesity (inhibition of weight gain or weight reduction) action, a body temperature raising action, for example, body temperature rise, cooling improvement, anti-obesity, visceral fat reduction, beauty, Expected to be effective in promoting metabolism, immune activation, anti-fatigue, antidepressant, etc. Further, a composition containing 1- (3 ′, 4 ′, 5′-trihydroxyphenyl) -3- (2``, 4 '', 6 ''-trihydroxyphenyl) -propan-2-ol obtained by the production method of the present invention The substance has excellent energy metabolism enhancing action, sympathetic nerve activity enhancing action, fat burning promoting action, body weight gain inhibiting or body weight reducing action, body temperature raising action, for example, body temperature rise, coldness Improvement, anti-obesity, visceral fat reduction, beauty, promotion of metabolism, immune activation, anti-fatigue, antidepressant, etc. can be expected.

Claims (4)

茶抽出液をラクトバチルス・ペントーサスに属する菌で発酵する工程を含むことを特徴とする、1-(3’,4’,5’-trihydroxyphenyl)-3-(2’’,4’’,6’’-trihydroxyphenyl)-propan-2-ol含有組成物の製造方法。   1- (3 ', 4', 5'-trihydroxyphenyl) -3- (2``, 4 '', 6, characterized by including a step of fermenting tea extract with a bacterium belonging to Lactobacillus pentosas '' -trihydroxyphenyl) -propan-2-ol-containing composition production method. 組成物中の1-(3’,4’,5’-trihydroxyphenyl)-3-(2’’,4’’,6’’-trihydroxyphenyl)-propan-2-olの含有量が0.13mg/mL以上である、請求項記載の製造方法。 The content of 1- (3 ', 4', 5'-trihydroxyphenyl) -3- (2``, 4 '', 6 ''-trihydroxyphenyl) -propan-2-ol in the composition is 0.13 mg / mL in a process according to claim 1, wherein more. 請求項又は記載の製造方法により得られた組成物を、飲食品の原料として使用することを特徴とする、飲食品の製造方法。 A method for producing a food or drink, wherein the composition obtained by the production method according to claim 1 or 2 is used as a raw material for the food or drink. 飲食品がエネルギー代謝亢進用である、請求項記載の製造方法。
The manufacturing method of Claim 3 whose food-drinks are for energy metabolism enhancement.
JP2017505328A 2015-03-09 2016-03-07 Tea fermentation Expired - Fee Related JP6412248B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2015046416 2015-03-09
JP2015046416 2015-03-09
JP2015046415 2015-03-09
JP2015046415 2015-03-09
PCT/JP2016/057009 WO2016143745A1 (en) 2015-03-09 2016-03-07 Fermented tea product

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018181503A Division JP6669829B2 (en) 2015-03-09 2018-09-27 Fermented tea

Publications (2)

Publication Number Publication Date
JPWO2016143745A1 JPWO2016143745A1 (en) 2017-12-28
JP6412248B2 true JP6412248B2 (en) 2018-10-24

Family

ID=56880159

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017505328A Expired - Fee Related JP6412248B2 (en) 2015-03-09 2016-03-07 Tea fermentation
JP2018181503A Expired - Fee Related JP6669829B2 (en) 2015-03-09 2018-09-27 Fermented tea

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018181503A Expired - Fee Related JP6669829B2 (en) 2015-03-09 2018-09-27 Fermented tea

Country Status (6)

Country Link
JP (2) JP6412248B2 (en)
AU (1) AU2016230139B2 (en)
MY (1) MY184881A (en)
NZ (1) NZ734801A (en)
TW (1) TWI681719B (en)
WO (1) WO2016143745A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6886571B2 (en) * 2016-09-21 2021-06-16 池田食研株式会社 Method for producing 4-ethylphenol
JP2018087171A (en) * 2016-11-29 2018-06-07 株式会社明治 Sympathetic nerve activating composition
JP6785141B2 (en) * 2016-12-09 2020-11-18 サントリーホールディングス株式会社 Basal metabolic rate enhancer
JP2021180619A (en) * 2020-05-18 2021-11-25 国立大学法人千葉大学 Fermented tea composition for controlling intestinal function and method of producing the same
JP2021020944A (en) * 2020-10-26 2021-02-18 サントリーホールディングス株式会社 Basal metabolism enhancer

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5568276B2 (en) * 2009-10-21 2014-08-06 三井農林株式会社 Method for producing catechin metabolites

Also Published As

Publication number Publication date
AU2016230139A1 (en) 2017-09-21
TWI681719B (en) 2020-01-11
AU2016230139B2 (en) 2018-10-18
JP2019011353A (en) 2019-01-24
WO2016143745A1 (en) 2016-09-15
JP6669829B2 (en) 2020-03-18
MY184881A (en) 2021-04-29
JPWO2016143745A1 (en) 2017-12-28
TW201642753A (en) 2016-12-16
NZ734801A (en) 2019-06-28

Similar Documents

Publication Publication Date Title
JP6669829B2 (en) Fermented tea
TWI551684B (en) Swiss lactic acid bacteria with high proteolytic activity
KR102323969B1 (en) Composition comprising extract post-fermented tea
KR102206628B1 (en) Novel Lactobacillus rhamnosus strain for preventing or treating obesity and the use thereof
WO2018117041A1 (en) Lipid metabolism-promoting composition including isoxanthohumol
Kim et al. Preparation and characterization of fermented dandelion (Taraxacum officinale) beverage using Lactobacillus acidophilus F46 having cinnamoyl esterase activity
KR101614929B1 (en) A pharmaceutical composition for treating cognitive and memory impairment
JP6471145B2 (en) Autonomic nerve regulator and diurnal rhythm improving agent for sedation
JP7041508B2 (en) Composition for improving circadian rhythm
KR20130130131A (en) Vinegar composition fermented with black garlic and preparation method thereof
JP6671367B2 (en) Anti-obesity composition containing cyclic dipeptide
WO2021131568A1 (en) Composition for suppressing or improving reduction in amount of physical activity
KR101535077B1 (en) The products containing probiotic Bifidobacterium lactis HY8101 having activity preventing from insulin resistance, which caused type 2 diabetes mellitus
KR102578389B1 (en) Novel Lactobacillus reuteri strain capable of improving fatty liver and use thereof
AU2018275937A1 (en) Composition for fatigue recovery and/or prevention of fatigue accumulation
KR102639561B1 (en) Composition for preventing, treating or improving metabolic disease including obesity, diabetes or fatty liver using Lactobacillus plantarum NCHBL-004 strain or culture medium thereof
JP7352570B2 (en) Composition for improving blood flow and composition for improving vascular endothelial function
KR102300960B1 (en) Probiotics-microcapsule in which curcumin is accumulated in cells and a method for producing the same
EP4166149A1 (en) Mitochondrial function-improving composition
JP2020184909A (en) Hypoglycemic agent and food/beverage containing said hypoglycemic agent
KR20210039970A (en) Composition for preventing, treating or improving obesity
JP6588742B2 (en) Immune function enhancer
KR20220002114A (en) Edible insect fermentation products fermented using probiotic strain and uses thereof
KR20230165104A (en) Composition for preventing, treating or improving metabolic disease comprising Lactobacillus kunkeei NCHBL-003 strain or culture medium thereof
KR20200109434A (en) Enzyme treated catechin product containing increased gallic acid, epicatechin and epigallocatechin content and preparation method thereof

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170817

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20170817

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180522

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180718

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180910

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180927

R150 Certificate of patent or registration of utility model

Ref document number: 6412248

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees